Federal Agency Outlines Psychedelic Research Priorities And Guidance For Studies Involving Animals, Adults And Children

Federal Agency Outlines Psychedelic Research Priorities And Guidance For Studies Involving Animals, Adults And Children
MJ moment

A federal health agency is giving researchers guidance on the types of studies it’s interested in funding for the development of psychedelic drugs to treat certain mental health conditions, pointing out limitations for animal-based research and rules for trials involving children. The National Institute of Mental Health (NIMH) published a notice of information last week, providing additional information about research criteria and priorities for psychedelic studies. “Psychedelic drugs such as psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), mescaline, and related compounds are being evaluated by the pharmaceutical industry for their therapeutic potential in treating depression, post-traumatic stress disorder, and other mental illnesses,” NIMH said. Notice of Information on NIMH's Considerations for Research Involving Psychedelics and Related Compounds https://t.co/Srf03EYpIZ — NIH Funding (@NIHFunding) November 15, 2022 “The hallucinogenic effects of psychedelics, their role in the larger psychotherapeutic process, and the poor predictive validity of current animal models in drug development for mental illness are critical factors that warrant careful consideration of the types of research questions that can be addressed using animal systems” it said. Hence, the agency’s notice is meant to lay out some ground rules for researchers who wish to contribute psychedelics research as part of its active grant programs for mental health treatment. Specifically, NIMH said it wanted to explain what it considers to be a “reasonable premise for pursuing basic mechanistic research on psychedelics and related compounds, and clarifies guidelines for reproducible and rigorous clinical research involving these agents.” For grant applications that propose using an animal model, the agency noted that such studies “are not well suited to assess the therapeutic efficacy of psychedelics.” Rather, they should be used “to link mechanisms downstream of receptor activation to adaptive changes in the function of circuits relevant to mental health.” “When determining funding priorities for animal studies investigating…

Excerpt only …
READ MORE BELOW
Source : Federal Agency Outlines Psychedelic Research Priorities And Guidance For Studies Involving Animals, Adults And Children

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.